1-4 of 4
Ram Ganapathi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Role of the 18:1 Lysophosphatidic Acid–Ovarian Cancer Immunoreactive Antigen Domain Containing 1 (OCIAD1)–Integrin Axis in Generating Late-Stage Ovarian Cancer

Chunyan Wang, Chad M. Michener, Jerome L. Belinson, Susan Vaziri, Ram Ganapathi, Saubhik Sengupta
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (6): 1709–1718.
https://doi.org/10.1158/1535-7163.MCT-09-1024
Published: 09 June 2010
View article titled, Role of the 18:1 Lysophosphatidic Acid–Ovarian Cancer Immunoreactive Antigen Domain Containing 1 (OCIAD1)–Integrin Axis in Generating Late-Stage Ovarian Cancer
Open the PDF for Role of the 18:1 Lysophosphatidic Acid–Ovarian Cancer Immunoreactive Antigen Domain Containing 1 (OCIAD1)–Integrin Axis in Generating Late-Stage Ovarian Cancer in another window
Journal Articles

Abstract C237: A phase I study of the alternating administration of ixabepilone and vinflunine every three weeks in patients with advanced cancer

Tarek Mekhail, Ram Ganapathi, Leila Alland, Claude George, Pasquale Benedetto, Lisa I. Sheehan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C237.
https://doi.org/10.1158/1535-7163.TARG-09-C237
Published: 10 December 2009
View article titled, Abstract C237: A phase I study of the alternating administration of ixabepilone and vinflunine every three weeks in patients with advanced cancer
Journal Articles

Sensitization of DNA damage–induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3σ and survivin

Susan A.J. Vaziri, Jason Hill, Kenichi Chikamori, Dale R. Grabowski, Nagio Takigawa, Mamta Chawla-Sarkar, Lisa R. Rybicki, Andrei V. Gudkov, Tarek Mekhail, Ronald M. Bukowski, Mahrukh K. Ganapathi, Ram Ganapathi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2005) 4 (12): 1880–1890.
https://doi.org/10.1158/1535-7163.MCT-05-0222
Published: 22 December 2005
View article titled, Sensitization of DNA damage–induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3σ and survivin
Open the PDF for Sensitization of DNA damage–induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3σ and survivin in another window
Journal Articles

A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors

David E. Weng, Paul A. Masci, Susan F. Radka, T. Elise Jackson, Patricia A. Weiss, Ram Ganapathi, Paul J. Elson, William B. Capra, Vann P. Parker, Jennifer A. Lockridge, J. Wayne Cowens, Nassim Usman, Ernest C. Borden
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2005) 4 (6): 948–955.
https://doi.org/10.1158/1535-7163.MCT-04-0210
Published: 14 June 2005
View article titled, A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors
Open the PDF for A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors in another window